<DOC>
	<DOCNO>NCT01303237</DOCNO>
	<brief_summary>This prospective , observational , multicentre , post marketing surveillance study collect safety efficacy information patient Locally Advanced Squamous Cell Carcinoma Head Neck ( LA SCCHN ) treat Cetuximab Radiotherapy ( RT ) base locally approve label .</brief_summary>
	<brief_title>A Post Marketing Surveillance Study Assess Safety Efficacy Cetuximab Plus Radiotherapy Locally Advanced Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>This prospective , non-randomized , observational , single arm , cohort study , wherein 200 patient unresectable LA SCCHN enrol . The eligibility patient decide Investigators base locally approve label . The patient treat Cetuximab combination RT duration 8 week follow 3 year . The objective study record safety efficacy information treatment combination general population .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion criterion per product label LA SCCHN approve India Health Authority Unresectable Locally Advanced Squamous Cell Carcinoma Head Neck Patient willing able give write Informed Consent Patient capable comply study data collection procedure Exclusion criterion per product label LA SCCHN approve India Health Authority</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>LA SCCHN</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>RT</keyword>
	<keyword>PMS</keyword>
</DOC>